FEATURED

XTANDI Practice and Patient Resources

Combined Proteomics, Metabolomics Analysis for RCC

Researchers used a sophisticated combination of proteomics and metabolomics to show how RCC reprograms its metabolism and evades the immune system.

Gastric Outlet Obstruction

Common GI symptoms experienced by patients with cancer can vary widely and determining an underlying malignancy can prove difficult.

Drug Showcase: LENVIMA (lenvatinib)

Indicated for thyroid cancer.

Tell your Nurse Navigator!

Join us for the ONA Navigation Summit meeting in Denver.

CD151—A Striking Marker for Cancer Therapy

Cluster of differentiation 151 (CD151) functions at various stages of cancer.

Multigene Panel Testing and Patient Counseling

Multigene panel technology is gaining favor, but tests are outpacing the molecular-epidemiological evidence base and models for patient counseling.

Adjuvant Chemo and Advanced Rectal Cancer

A recent letter in JCO discusses whether patients with locally advanced rectal cancer need adjuvant chemotherapy.

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

Viewpoints

Study Suggests Renal Cell Carcinoma Reprograms its Metabolism to Evade Immune System

Study Suggests Renal Cell Carcinoma Reprograms its Metabolism to Evade Immune System

Researchers used a sophisticated combination of proteomics and metabolomics to show how RCC reprograms its metabolism and evades the immune system.

Do Patients with Locally Advanced Rectal Cancer Benefit from Adjuvant Chemotherapy?

Do Patients with Locally Advanced Rectal Cancer Benefit from Adjuvant Chemotherapy?

A recent letter in JCO discusses whether patients with locally advanced rectal cancer need adjuvant chemotherapy.

Feature Articles

Malignant Gastric Outlet Obstruction

Malignant Gastric Outlet Obstruction

Common gastrointestinal symptoms experienced by patients with cancer can vary widely and determining an underlying malignancy can prove difficult.

CD151—A Striking Marker for Cancer Therapy

CD151—A Striking Marker for Cancer Therapy

[Biomarkers in Cancer] Cluster of differentiation 151 (CD151) functions at various stages of cancer, including metastatic cascade and primary tumor growth, reinforcing the importance of CD151 as a target in oncology.

Featured Videos

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs